In vivo gene therapy using intraosseous delivery of a lentiviralgene construct

Abstract

Methods, compositions, and systems for treating subject(s) in need of plasma Factor VIII, particularly a subject having preexisting anti-FVIII inhibitory antibodies, are provided. The methods involve administering to the subject a therapeutically effective amount of an inflammation suppressor, a therapeutically effective amount of a CD8+ T cell depleting agent, and a therapeutically effective amount of a composition comprising a lentiviral vector (LV) comprising an optimized FVIII expression cassette expressibly linked to a megakaryocyte-specific promoter. Such methods, compositions, and systems are useful to treat subjects with blood clotting disorder(s), such as hemophilia A.

What is claimed is: 
     
         1 . A method of treating a subject in need of plasma Factor VIII, comprising:
 administering to the subject a therapeutically effective amount of an inflammation suppressor;   administering to the subject a therapeutically effective amount of a CD8+ T cell depleting agent; and   administering to the subject a therapeutically effective amount of a composition comprising a lentiviral vector comprising an optimized FVIII expression cassette expressibly linked to a megakaryocyte-specific promoter, wherein administration is via:
 intraosseous (IO) infusion; 
 intravenous (IV) delivery; or 
 intranasal (IN) or inhaled delivery. 
   
     
     
         2 . The method of  claim 1 , wherein the inflammation suppressor comprises dexamethasone (Dex). 
     
     
         3 . The method of  claim 2 , wherein the dexamethasone is administered in doses of 100 mg/kg at −24 h before, −4 h before, 4 h after, and 24 h after administration of the LV. 
     
     
         4 . The method of  claim 1 , wherein the CD8+ T cell depleting agent comprises an anti-CD8 antibody. 
     
     
         5 . The method of  claim 4 , wherein the CD8+ T cell depleting agent is an anti-CD8α mAb administered in doses of 4 mg/kg at −1 day before, 4 days after, and 11 days after delivery of the LV. 
     
     
         6 . The method of  claim 1 , wherein the megakaryocyte-specific promoter is a GP1b-alpha promoter. 
     
     
         7 . The method of  claim 1 , which method does not comprise pre-conditioning or myeloablative treatment of the subject. 
     
     
         8 . The method of  claim 1 , wherein the IO infusion is carried out at a rate of 2 μL/min to 15 μL/min, 5 μL/min to 12 μL/min, or at no more than 10 μL/min. 
     
     
         9 . The method of  claim 1 , wherein the IO infusion is carried out at a rate of 0.01 mL/min to 0.5 mL/min, 0.05 mL/min to 0.3 mL/min, 0.1 mL/min to 0.25 mL/min, or at no more than 0.4 mL/min. 
     
     
         10 . The method of  claim 1 , wherein the IO infusion is carried out over a period of no more than 45 minutes. 
     
     
         11 . The method of  claim 1 , wherein the optimized FVIII expression cassette comprises hF8X10 K12 (SEQ ID NO: 1) or hF8/N6K12RH (SEQ ID NO: 2). 
     
     
         12 . The method of  claim 1 , wherein the lentiviral vector comprises SEQ ID NO: 3 or SEQ ID NO: 4, or a functional variant thereof. 
     
     
         13 . The method of any one of the previous claims, which is a method for treating a hemostasis related disorder in the subject, and the subject is in need of such treatment. 
     
     
         14 . The method of any one of the previous claims, wherein the subject has hemophilia A (hemA), von Willebrand disease, bleeding associated with trauma or injury, thrombosis, thrombocytopenia, stroke, coagulopathy, disseminated vascular coagulation (DIC), or over-anticoagulation treatment disorder. 
     
     
         15 . The method of any one of the previous claims, wherein the subject is a HemA subject with preexisting anti-FVIII inhibitory antibodies. 
     
     
         16 . A method of treating a subject in need of plasma Factor VIII, essentially as described herein.